The biogenic methanobactin is an effective chelator for copper in a rat model for Wilson disease

Journal of Trace Elements in Medicine and Biology

Volumn 25, Issue 1, 2011, Pages 36-41

  Summer, Karl H ^a   Lichtmannegger, Josef ^a   Bandow, Nathan ^b   Choi, Don W ^b   DiSpirito, Alan A ^b   Michalke, Bernhard ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b IOWA STATE UNIVERSITY   (United States)

Author keywords

Copper chelator; Metallothionein; Methanobactin; Treatment; Wilson disease

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CHELATING AGENT; COPPER; METALLOTHIONEIN; METHANOBACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL STRAIN; BILE; CHELATION; COPPER BLOOD LEVEL; COPPER TOXICITY; DRUG MECHANISM; HISTOPATHOLOGY; LIVER CYTOSOL; LIVER LEVEL; METHYLOSINUS TRICHOSPORIUM; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY; WILSON DISEASE;

ANIMALS; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; HEPATOLENTICULAR DEGENERATION; IMIDAZOLES; OLIGOPEPTIDES; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET;

ANIMALIA; BACTERIA (MICROORGANISMS); METHYLOSINUS TRICHOSPORIUM; RATTUS;

EID: 79952706128     PISSN: 0946672X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtemb.2010.12.002     Document Type: Article

References (31)

1. Balamurugan K., Schaffner W. Copper homeostasis in eukaryotes: teetering on a tightrope. Biochim Biophys Acta 2006, 1763:737-746.
2. Cox D.W., Moore S.D.J. Copper transporting P-type ATPases and human disease. Bioenerg Biomembr 2002, 34:333-338.
3. Roberts E.A., Schilsky M.L. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008, 47:2089-2111.
4. Mulder T.P., Janssens A.R., Verspaget H.W., van Hattum J., Lamers C.B. Metallothionein concentration in the liver of patients with Wilson's disease, primary biliary cirrhosis, and liver metastasis of colorectal cancer. J Hepatol 1992, 16:346-350.
5. Brewer G.J., Terry C.A., Aisen A.M., Hill G.M. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987, 44:490-493.
6. Brewer G.J., Askari F., Lorincz M.T., Carlson M., Schilsky M., Kluin K.J., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006, 63:521-527.
7. Wu J., Forbes J.R., Chen H.S., Cox D.W. The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene. Nat Genet 1994, 7:541-545.
8. Suzuki K.T., Kanno S., Misawa S., Aoki Y. Copper metabolism leading to and following acute hepatitis in LEC rats. Toxicology 1995, 97:81-92.
9. Suzuki K.T., Kanno S., Misawa S., Sumi Y. Changes in hepatic copper distribution leading to hepatitis in LEC rats. Res Commun Chem Pathol Pharmacol 1993, 82:217-224.
10. Ahmed S., Deng J., Borjigin J. A new strain of rat for functional analysis of PINA. Brain Res Mol Brain Res 2005, 137:63-69.
11. Kim H.J., Graham D.W., DiSpirito A.A., Alterman M.A., Galeva N., Larive C.K., et al. a copper-acquisition compound from methane-oxidizing bacteria. Science 2004, 305:1612-1615.
12. Choi D.W., Zea C.J., Do Y.S., Semrau J.D., Antholine W.E., Hargrove M.S., et al. Spectral, kinetic, and thermodynamic properties of Cu(I) and Cu(II) binding by methanobactin from Methylosinus trichosporium OB3b. Biochemistry 2006, 45:1442-1453.
13. Behling L.E., Hartsel S.C., Lewis D.E., DiSpirito A.A., Masterson L.R., Veglia G., et al. NMR mass spectroscopy, and chemical evidence reveal a different chemical structure for methanobactin that contains oxazolone rings. J Am Chem Soc 2008, 130:12604-12605.
14. Choi D.W., Antholine W.E., Do Y.S., Semrau J.D., Kisting C.J., Kunz R.C., et al. Effect of methanobactin on the activity and electron paramagnetic resonance spectra of the membrane-associated methane monooxygenase in Methylococcus capsulatus Bath. Microbiology 2005, 151:3417-3426.
15. Choi D.W., Semrau J.D., Antholine W.E., Hartsel S.C., Anderson R.C., Carey J., et al. Oxidase, superoxide dismutase, and hydrogen peroxide reductase activities of methanobactin from type I and II methanotrophs. J Inorg Biochem 2008, 102:1571-1580.
16. Balasubramanian R., Rosenzweig A.C. Copper methanobactin: a molecule whose time has come. Curr Opin Chem Biol 2008, 12:245-249.
17. Whittenbury R., Phillips K.C., Wilkinson J.F. Enrichment, isolation and some properties of methane-utilizing bacteria. J Gen Microbiol 1970, 61:205-218.
18. Kim H.J., Galeva N., Larive C.K., Alterman M., Graham D.W. Purification and physical-chemical properties of methanobactin: a chalkophore from Methylosinus trichosporium OB3b. Biochemistry 2005, 44:5140-5148.
19. Klein D., Lichtmannegger J., Heinzmann U., Summer K.H. Dissolution of copper-rich granules in hepatic lysosomes by d-penicillamine prevents the development of fulminant hepatitis in Long-Evans cinnamon rats. J Hepatol 2000, 32:193-201.
20. Suzuki K.T., Yamamoto K., Kanno S., Aoki Y., Takeichi N. Selective removal of copper bound to metallothionein in the liver of LEC rats by tetrathiomolybdate. Toxicology 1993, 83:149-158.
21. 35S]-labeled metallothionein in vitro: implications for Wilson's disease therapy. J Inorg Biochem 1991, 41:87-92.
22. McQuaid A., Lamand M., Mason J. The interactions of penicillamine with copper in vivo and the effect on hepatic metallothionein levels and copper/zinc distribution: the implications for Wilson's disease and arthritis therapy. J Lab Clin Med 1992, 119:744-750.
23. Banci L., Bertini I., Ciofi-Baffoni S., Kozyreva T., Zovo K., Palumaa P. Affinity gradients drive copper to cellular destinations. Nature 2010, 465:645-648.
24. Choi D.W., Do Y.S., Zea J.C., McEllistrem M.T., Lee S.W., Semrau J.D., et al. Spectral and thermodynamic properties of Ag(I), Au(III), Cd(II), Co(II), Fe(III), Hg(II), Mn(II), Pb(II), U(VI), and Zn(II) binding by methanobactin from Methylosinus trichosporium OB3b. J Inorg Biochem 2006, 100:5150-5161.
25. Yang X., Gandhi Y.A., Duignan D.B., Morris M.E. Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. AAPS J 2009, 11:511-525.
26. Sone K., Maeda M., Wakabayashi K., Takeichi N., Mori M., Sugimura T., et al. Inhibition of hereditary hepatitis and liver tumor development in Long-Evans cinnamon rats by the copper-chelating agent trientine dihydrochloride. Hepatology 1996, 23:764-770.
27. Scheinberg I.H., Sternlieb I., Schilsky M., Stockert R.J. Penicillamine may detoxify copper in Wilson's disease. Lancet 1987, 2:95.
28. Ogra Y., Ohmichi M., Suzuki K.T. Mechanisms of selective copper removal by tetrathiomolybdate from metallothionein in LEC rats. Toxicology 1996, 106:75-83.
29. Ogra Y., Miyayama T., Anan Y. Effect of glutathione depletion on removal of copper from LEC rat livers by tetrathiomolybdate. Inorg Biochem 2010, 104:858-862.
30. Ogra Y., Chikusa H., Suzuki K.T. Metabolic fate of the insoluble copper/tetrathiomolybdate complex formed in the liver of LEC rats with excess tetrathiomolybdate. J Inorg Biochem 2000, 78:123-128.
31. Linn F.H., Houwen R.H., van Hattum J., van der Kleij S., van Erpecum K.J. Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. Hepatology 2009, 50:1442-1452.